LOGIN TO YOUR ACCOUNT

Username
Password
Remember Me
Or use your Academic/Social account:

CREATE AN ACCOUNT

Or use your Academic/Social account:

Congratulations!

You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.

Important!

Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message

CREATE AN ACCOUNT

Name:
Username:
Password:
Verify Password:
E-mail:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Bartlett, C; Hooper, L; Ebrahim, S (2001)
Publisher: Massachusetts Medical Society
Languages: English
Types: Article
Subjects:
  • The results below are discovered through our pilot algorithms. Let us know how we are doing!

    • 1. Sacks FM, Svetkey LP, Vollmer WM, et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. N Engl J Med 2001;344:3-10.
    • 2. Graudal NA, Galloe AM, Garred P. Effects of sodium restriction on blood pressure, renin, aldosterone, catecholamines, cholesterols, and triglyceride: a meta-analysis. JAMA 1998;279:1388-91.
    • 3. He J, Ogden LG, Vupputuri S, Bazzano LA, Loria C, Whelton PK. Dietary sodium intake and subsequent risk of cardiovascular disease in overweight adults. JAMA 1999;282:2027-34.
    • 4. Alderman MH, Cohen H, Madhavan S. Dietary sodium intake and mortality: the National Health and Nutrition Examination Survey (NHANES I). Lancet 1998;351:781-5.
    • 1. McCarron DA, Morris CD, Cole C. Dietary calcium in human hypertension. Science 1982;217:267-9.
    • 2. McCarron DA, Morris CD, Henry HJ, Stanton JL. Blood pressure and nutrient intake in the United States. Science 1984;224:1392-8.
    • 3. Patterson RE, Satia JA, Kristal AR , Neuhouser ML, Drewnowski A. Is there a consumer backlash against the diet and health message? J Am Diet Assoc 2001;101:37-41.
    • 4. Freedman DA, Petitti DB. Salt and blood pressure: conventional wisdom reconsidered. Evaluation Review (in press).
    • 1. Stamler J, Stamler R , Neaton JD. Blood pressure, systolic and diastolic, and cardiovascular risks. Arch Intern Med 1993;153:598-615.
    • 2. MacMahon S, Peto R , Cutler J, et al. Blood pressure, stroke, and coronary heart disease. I. Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990;335:765-74.
    • 3. Collins R , Peto R. Antihypertensive drug therapy: effects on stroke and coronary heart disease. In: Swales JE, ed. Textbook of hypertension. Oxford, England: Blackwell Scientific, 1994:1156-64.
    • 4. Graudal NA, Galloe AM, Garred P. Effects of sodium restriction on blood pressure, renin, aldosterone, catecholamines, cholesterols, and triglyceride: a meta-analysis. JAMA 1998;279:1388-91.
    • 1. The Hypertension Prevention Trial Research Group. The Hypertension Prevention Trial: three-year effects of dietary changes on blood pressure. Arch Intern Med 1990;150:153-62.
    • 2. The effects of nonpharmacologic interventions on blood pressure of persons with high normal levels: results of the Trials of Hypertension Prevention, Phase I. JAMA 1992;267:1213-20. [Erratum, JAMA 1992;267: 2330.]
    • 3. The Trials of Hypertension Prevention Collaborative Research Group. Effects of weight loss and sodium reduction intervention on blood pressure and hypertension incidence in overweight people with high-normal blood pressure: the Trials of Hypertension Prevention, Phase II. Arch Intern Med 1997;157:657-67.
    • 4. Whelton PK, Appel LJ, Espeland MA, et al. Sodium reduction and weight loss in the treatment of hypertension in older persons: a randomized controlled trial of nonpharmacologic interventions in the elderly (TONE). JAMA 1998;279:839-46.
    • 5. Navar LG. The kidney in blood pressure regulation and development of hypertension. Med Clin North Am 1997;81:1165-98.
    • 1. Meade TW, Cooper JA, Peart WS. Plasma renin activity and ischemic heart disease. N Engl J Med 1993;329:616-9.
    • 2. Alderman MH, Cohen H, Madhavan S. Dietary sodium intake and mortality: the National Health and Nutrition Examination Survey (NHANES I). Lancet 1998;351:781-5.
    • 3. Stamler J, Neaton JD, Wentworth DN. Blood pressure (systolic and diastolic) and risk of fatal coronary heart disease. Hypertension 1989;13: Suppl I:I-2-I-12.
    • 4. Weinberger MH, Miller JZ, Luft FC, Grim CE, Fineberg NS. Definitions and characteristics of sodium sensitivity and blood pressure resistance. Hypertension 1986;8:Suppl II:II-127-II-134.
    • 5. MacGregor GA, Markandu ND, Sagnella GA, Singer DR, Cappuccio FP. Double-blind study of three sodium intakes and long-term effects of sodium restriction in essential hypertension. Lancet 1989;2:1244-7.
    • 1. Committee on Infectious Diseases. Recommended childhood immunization schedule: United States, January-December 2001. Pediatrics 2001; 107:202-4.
    • 2. Black S, Shinefield H, Fireman B, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Pediatr Infect Dis J 2000;19:187-95.
    • 1. Eskola J, Kilpi T, Palmu A, et al. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N Engl J Med 2001;344:403-9.
    • 1. Del Mar C, Glasziou P, Hayem M. Are antibiotics indicated as initial treatment for children with acute otitis media? A meta-analysis. BMJ 1997; 314:1526-9.
    • 2. Damoiseaux RAMJ, van Balen FAM, Hoes AW, Verheij TJ, de Melker RA. Primary care based randomised, double blind trial of amoxicillin versus placebo for acute otitis media in children aged under 2 years. BMJ 2000;320:350-4.
    • 3. Little P, Gould C, Williamson I, Moore M, Warner G, Dunleavy J. Pragmatic randomised controlled trial of two prescribing strategies for childhood acute otitis media. BMJ 2001;322:336-42.
    • 1. Spratt BG, Greenwood BM. Prevention of pneumococcal disease by vaccination: does serotype replacement matter? Lancet 2000;356:1210-1.
    • 2. Perdue DG, Bulkow LR, Gellin BG, et al. Invasive Haemophilus influenzae disease in Alaskan residents aged 10 years and older before and after infant vaccination programs. JAMA 2000;283:3089-94.
    • 3. Ramsay ME, Andrews N, Kaczmarski EB, Miller E. Efficacy of meningococcal serogroup C conjugate vaccine in teenagers and toddlers in England. Lancet 2001;357:195-6.
    • 4. Lipsitch M. Bacterial vaccines and serotype replacement: lessons from Haemophilus influenzae and prospects for Streptococcus pneumoniae. Emerg Infect Dis 1999;5:336-45.
    • 1. Black S, Shinefield H, Fireman B, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Pediatr Infect Dis J 2000;19:187-95.
    • 1. Lieu TA, Ray GT, Black SB, et al. Projected cost-effectiveness of pneumococcal conjugate vaccination of healthy infants and young children. JAMA 2000;283:1460-8.
    • 2. Black S, Shinefield H, Fireman B, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Pediatr Infect Dis J 2000;19:187-95.
    • 3. Shinefield HR, Black S. The efficacy and safety of heptavalent pneumococcal conjugate vaccine in children. Presented at the Millennium Second World Congress on Vaccines and Immunization, Liège, Belgium, August 29-September 3, 2000. abstract. 1. McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 2001;344:333-40. To the Editor: McClung et al. state that “complete follow-up data were available for 64 percent of the women.” 1. Schott AM, Cormier C, Hans D, et al. How hip and whole-body bone mineral density predict hip fracture in elderly women: the EPIDOS Prospective Study. Osteoporos Int 1998;8:247-54.
    • 2. Mazess RB, Barden H. Bone density of the spine and femur in adult white females. Calcif Tissue Int 1999;65:91-9.
    • 3. Dargent-Molina P, Favier F, Grandjean H, et al. Fall-related factors and risk of hip fracture: the EPIDOS prospective study. Lancet 1996;348:145- 9. [Erratum, Lancet 1996;348:416.] 325 170 4 liters of intravenous fluids; 20 gµ/kg/min of dopamine; 10 gµ/kg/min of dobutamine; 14 gµ/kg/min of norepinephrine; 5 mg of intravenous glucagon 2 liters of intravenous fluids; 4 g of calcium gluconate; 20 gµ/kg/min of dopamine; 10 gµ/kg/min of dobutamine 0.5 0.5 6 6 1. Litovitz TL, Klein-Schwartz W, Caravati EM, Youniss J, Crouch B, Lee S. 1998 Annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med 1999;17: 435-87.
    • 2. Enyeart JJ, Price WA, Hoffman DA, Woods L. Profound hyperglycemia and metabolic acidosis after verapamil overdose. J Am Coll Cardiol 1983; 2:1228-31.
    • 3. Yuan TH, Kerns WP II, Tomaszewski CA, Ford MO, Kline JA. Insulinglucose as adjunctive therapy for severe calcium channel antagonist poisoning. J Toxicol Clin Toxicol 1999;37:463-74.
    • 4. Kline JA, Leonova E, Raymond RM. Beneficial myocardial metabolic effects of insulin during verapamil toxicity in the anesthetized canine. Crit Care Med 1995;23:1251-63.
    • 5. Ohta M, Nelson J, Nelson D, Meglasson MD, Erecinska M. Effect of Ca++ channel blockers on energy level and stimulated insulin secretion in isolated rat islets of Langerhans. J Pharmacol Exp Ther 1993;264:35-40. Correspondence Copyright © 2001 Massachusetts Medical Society. 1722 · N Engl J Med, Vol. 344, No. 22 · May 31, 2001 · www.nejm.org
  • No related research data.
  • No similar publications.

Share - Bookmark

Download from

Cite this article